Personalis (NASDAQ:PSNL) Price Target Lowered to $8.00 at HC Wainwright

Personalis (NASDAQ:PSNLFree Report) had its price objective decreased by HC Wainwright from $11.00 to $8.00 in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on PSNL. Lake Street Capital lifted their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $7.25 price objective on shares of Personalis in a report on Wednesday, January 8th.

Check Out Our Latest Stock Analysis on Personalis

Personalis Stock Down 5.1 %

Shares of PSNL opened at $5.81 on Monday. Personalis has a 52 week low of $1.12 and a 52 week high of $7.20. The stock has a market cap of $410.48 million, a P/E ratio of -3.46 and a beta of 1.75. The business’s 50 day moving average price is $4.87 and its 200-day moving average price is $4.72.

Personalis (NASDAQ:PSNLGet Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The company had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same period in the prior year, the company posted ($0.51) earnings per share. On average, equities analysts anticipate that Personalis will post -1.37 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PSNL. ARK Investment Management LLC grew its position in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after purchasing an additional 723,637 shares during the period. abrdn plc bought a new stake in shares of Personalis in the fourth quarter worth $1,722,000. Walleye Capital LLC purchased a new stake in Personalis during the third quarter valued at $897,000. Jane Street Group LLC lifted its holdings in Personalis by 154.3% in the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after acquiring an additional 99,671 shares during the period. Finally, Geode Capital Management LLC boosted its position in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after purchasing an additional 83,068 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

(Get Free Report)

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

Further Reading

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.